ライフサイエンスコーパス: myosin light chain kinase

1 virtually abolished by direct inhibition of myosin light chain kinase.

2 lmodulin-binding domain of the smooth muscle myosin light chain kinase.

3 on T cell beta-integrin function, as well as myosin light chain kinase.

4 on myosin activity and regulated by RhoA and myosin light chain kinase.

5 to phosphorylation of LC20 via activation of myosin light chain kinase.

6 a2+/calmodulin pathway, a known activator of myosin light chain kinase.

7 f p21-activated kinase (Pak), caldesmon, and myosin light chain kinase.

8 istent with an activating phosphorylation by myosin light chain kinase.

9 rylation of RLC by Ca2+/calmodulin-dependent myosin light chain kinase.

10 protein kinase II but not with smooth muscle myosin light chain kinase.

11 altered with regulatory segments from either myosin light chain kinase.

12 calmodulin-binding domain from smooth muscle myosin light chain kinase.

13 (T18A/S19A) that cannot be phosphorylated by myosin light chain kinase.

14 LC20) at the same peptides phosphorylated by myosin light chain kinase.

15 )) at Ser(19) by Ca(2+)/calmodulin-dependent myosin light chain kinase.

16 mplitude and partly by a mechanism involving myosin light chain kinase.

17 ransfecting cells with constitutively active myosin light-chain kinase.

18 20), the CaM-binding domain of smooth muscle myosin light-chain kinase.

19 n observed in the complex of calmodulin with myosin light-chain kinase.

20 um channels and calcium/calmodulin-dependent myosin light-chain kinase.

21 in II heavy chain (MHC) and the long form of myosin light-chain kinase.

22 ng region closely related to the 130-150 kDa myosin light chain kinases.

23 etchin-MLCK that are analogous to vertebrate Myosin light chain kinases.

24 phorylation of its regulatory light chain by myosin light chain kinase A (MLCK-A), an unconventional

25 p-800, Arg-812, and Leu-813 in smooth muscle myosin light chain kinase abrogated calmodulin-dependent

26 ced cell invasion, but not survival requires myosin light chain kinase activation and myosin light ch

27 In turn, IL-1beta increased NF-kappaB and myosin light chain kinase activation in intestinal epith

28 with cGMP-mediated decreases in calcium and myosin light chain kinase activity, could accelerate lig

29 endent myosin light chain phosphorylation by myosin light chain kinase and actin stress fiber formati

30 act conformation adopted by CaM upon binding myosin light chain kinase and CaM-dependent protein kina

31 osphorylated by Ca(2+) /calmodulin-dependent myosin light chain kinase and dephosphorylated by myosin

32 development in ileal smooth muscle depend on myosin light chain kinase and MLCP activities without ch

33 e activities of Ca(2+) /calmodulin-dependent myosin light chain kinase and myosin light chain phospha

34 is determined by the relative activities of myosin light chain kinase and myosin light chain phospha

35 is modulated by the antagonistic activity of myosin light chain kinase and myosin light chain phospha

36 tingly, AJC disassembly was not dependent on myosin light chain kinase and myosin phosphatase.

37 s indicate that Ca(2+)/calmodulin-stimulated myosin light chain kinase and p160 Rho-associated coiled

38 Myosin light chain kinase and phosphatase activities are

39 Both myosin light chain kinase and Rho-associated kinase acte

40 lated through two myosin-signaling pathways, myosin light chain kinase and Rho-associated kinase.

41 esponding to the CaM-binding sites of smooth myosin light chain kinase and ryanodine receptor.

42 Skeletal muscle myosin light chain kinase and the catalytically active c

43 lated these recombinant species with cardiac myosin light chain kinase and zipper-interacting protein

44 atalytic cores of skeletal and smooth muscle myosin light chain kinases and Ca2+/calmodulin-dependent

45 contraction of actin filaments by activating myosin light-chain kinase and myosin II behind the leadi

46 relaxation of smooth muscle are regulated by myosin light-chain kinase and myosin phosphatase through

47 to elevated Rho activity, phosphorylation of myosin light chain kinase, and enhanced tensile stress f

48 in kinase C, phosphatidyl inositol-3-kinase, myosin light chain kinase, and intracellular protein tyr

49 RT-PCR analysis of tight junction proteins, myosin light chain kinase, and proinflammatory cytokine

50 nase A, Ca2+/calmodulin-dependent kinase II, myosin light chain kinase, and protein kinase G inhibito

51 iven that inhibition of nonmuscle myosin II, myosin light chain kinase, and Rho kinase all abrogate i

52 density and progressed independently of Rac, myosin light chain kinase, and Rho kinase, suggesting a

53 including methionine sulfoxide reductase A, myosin light chain kinase, and Runt-related transcriptio

54 tractile proteins alpha-smooth muscle actin, myosin light chain kinase, and SM22.

55 in action, including Mal2, Akap12, gelsolin, myosin light chain kinase, annexin-2, and Hsp70, manifes

56 e calmodulin-binding domain of smooth muscle myosin light chain kinase are also compared with the CaM

57 y shown that residues 1-142 of smooth muscle myosin light chain kinase are necessary for high-affinit

58 measuring the stabilization of calmodulin by myosin light chain kinase at dramatically higher unfoldi

59 h of these mutations significantly decreased myosin light chain kinase binding to myofilaments in vit

60 Myosin light chain kinase binds to actin-containing fila

61 Myosin light chain kinase binds to the actomyosin-contai

62 M, cytochalasin D, and inhibitors of Rho and myosin light chain kinases blocked both responses.

63 The C-terminal truncated myosin light chain kinase bound to detergent-washed smoo

64 The initial rise in contractility required myosin light chain kinase but not Rho-kinase, but both s

65 calmodulin-binding peptide of smooth muscle myosin light chain kinase but not with the calmodulin ki

66 dependent on tumor necrosis factor alpha and myosin light-chain kinase but not interleukin-1beta.

67 Downstream of Ca2+, both calmodulin and myosin light chain kinase, but not calcineurin, are invo

68 Inhibition of myosin light chain kinase, but not protein kinase C or t

69 The full-length and the C-terminal truncated myosin light chain kinases, but not myosin light chain k

70 Blocking beta1-integrin, Src, ERK, or myosin light chain kinase by short hairpin RNA or pharma

71 nship expected for competitive inhibition of myosin light chain kinase by these drugs and is seen at

72 from IP(3)R that displaces CaM from Trp3, a myosin light chain kinase Ca(2+)/CaM binding peptide tha

73 a peptide corresponding to the smooth muscle myosin light chain kinase calmodulin-binding domain (smM

74 Inhibitors of the classical CAM effectors myosin light chain kinase, CAM-dependent protein kinases

75 dependent on myosin in that an inhibitor of myosin light chain kinase can arrest DRM reorganization

76 ynaptic terminals, I show that inhibitors of myosin light chain kinase can block mobilization of the

77 Elevation of cAMP did not alter myosin light chain kinase catalytic activity.

78 site to 0.45 mol of phosphate/mol by cardiac myosin light chain kinase (cMLCK) increases Ca(2+) sensi

79 sphorylates MLC2v in cardiomyocytes, cardiac myosin light-chain kinase (cMLCK), yet the role(s) playe

80 Truncated myosin light chain kinases containing the catalytic core

81 Nonmuscle myosin light-chain kinase contributes to atherosclerosis

82 is obtained by using a constitutively active Myosin Light Chain Kinase (ctMLCK) to selectively elevat

83 ced by coexpression of constitutively active myosin light chain kinase (ctMLCK), which increases myos

84 elial architecture require a Rho kinase- and myosin light chain kinase-dependent increase in the phos

85 Upon photodisruption and recoil, myosin light chain kinase-dependent SFs located along th

86 release of both fatty acids was calcium- and myosin light chain kinase-dependent, suggesting that bot

87 ML-7, an inhibitor of myosin light chain kinase, diminished the phloretin-sens

88 Pharmacologic inhibition of myosin II or myosin light chain kinase dramatically reduced spreading

89 Intestinal myosin light chain kinase expression decreased in Cd14-d

90 inositol 3-kinase attenuated alpha-actin and myosin light-chain kinase expression.

91 Members of the titin/myosin light chain kinase family play an essential role

92 domains and is homologous to proteins of the myosin light chain kinase family.

93 lly expressed gene (Speg) is a member of the myosin light chain kinase family.

94 terminal regulatory segment of smooth muscle myosin light chain kinase folds back on its catalytic co

95 iac light chain phosphorylation, we cloned a myosin light chain kinase from a human heart and have id

96 Thus, dissociation of myosin light chain kinase from actin-containing thin fil

97 econd-messenger protein calmodulin (CaM) and myosin light chain kinase from skeletal muscle (skMLCK)

98 MEKK-1 also played an essential role in myosin light chain kinase gene activation.

99 se results define a new and specific role of myosin light chain kinase in cardiac myocytes, which may

100 osphorylated by a dedicated Ca(2+)-dependent myosin light chain kinase in fast skeletal muscle, where

101 very after photobleaching of the full-length myosin light chain kinase in saponin-permeable cells sho

102 n of myosin phosphatase or inhibition of the myosin light-chain kinase in nonmalignant cells could re

103 arization and motility, but treatment with a myosin light chain kinase inhibitor (ML-7) or the actin-

104 mbin-induced rounding is also blocked by the myosin light chain kinase inhibitor KT5926.

105 The myosin light chain kinase inhibitor ML-7 and the myosin

106 Concordantly, treatment of cells with the myosin light chain kinase inhibitor ML-7 or the myosin I

107 in conditioned medium, including serotonin, myosin light chain kinase inhibitor, and phorbol ester.

108 r, blockade of MRLC phosphorylation with the myosin light chain kinase inhibitor, ML-7, or the rho ki

109 ing was also completely inhibited by ML-9, a myosin light chain kinase inhibitor.

110 ctin-filament disrupting drugs but also by a myosin light chain kinase inhibitor.

111 The myosin light-chain kinase inhibitor, KT5926, also blocke

112 fening response was not inhibited by ML-7, a myosin light-chain kinase inhibitor, or BAPTA, an intrac

113 fonyl)-2-methyl-piperazine (H-7), a proposed myosin light-chain kinase inhibitor; and the direct acti

114 inant negative mutant RhoA(T19N) and Rho and myosin light chain kinase inhibitors.

115 lmodulin-binding domain of the smooth muscle myosin light chain kinase is examined using 15N and 2H N

116 A Ca(2+)/calmodulin-activated myosin light chain kinase is expressed only in cardiac m

117 n catalyzed by a Ca(2+)/calmodulin-dependent myosin light chain kinase is important in the initiation

118 us, the N terminus and not the C terminus of myosin light chain kinase is necessary for high affinity

119 were mimicked in (+/+) NMJs by inhibitors of myosin light chain kinase, known to affect vesicle mobil

120 ression of myosin phosphatase and/or reduced myosin light-chain kinase levels.

121 Our results also suggest that PKC and MLCK (myosin light chain kinase) may be downstream effectors o

122 at neutrophil transmigration is regulated by myosin light chain kinase-mediated endothelial cell cont

123 ion development at the leading edge requires myosin light chain kinase-mediated myosin II contractili

124 Ca(2+)-dependent calmodulin/myosin light-chain kinase-mediated contraction was exami

125 y examining the effects of two inhibitors of myosin light chain kinase, ML7 and KT5926.

126 om the CaM binding domain of skeletal muscle myosin light chain kinase (MLCK(579-595)), which contain

127 he well-known, muscle-specific smooth muscle myosin light chain kinase (MLCK) (smMLCK) and skeletal m

128 hains by the catalytic COOH-terminal half of myosin light chain kinase (MLCK) activates myosin II in

129 uce barrier defects that are associated with myosin light chain kinase (MLCK) activation and increase

130 actor (alpha) (TNF) signaling and epithelial myosin light chain kinase (MLCK) activation.

131 aphase-anaphase transition by Ca2+-dependent myosin light chain kinase (MLCK) activity and is maintai

132 dominantly by Rho kinase in both cell types, myosin light chain kinase (MLCK) also appeared to contro

133 served between CaM and peptides derived from myosin light chain kinase (MLCK) and CaM-dependent kinas

134 on of myosin regulatory light chain (RLC) by myosin light chain kinase (MLCK) and myosin binding prot

135 thway involving the MAP kinases MEK and ERK, myosin light chain kinase (MLCK) and Myosin IIB.

136 e activities of Ca(2+) /calmodulin-dependent myosin light chain kinase (MLCK) and myosin light chain

137 ve activities of Ca(2+)-calmodulin-dependent myosin light chain kinase (MLCK) and myosin light chain

138 Activation of myosin light chain kinase (MLCK) and other kinases was s

139 tivation of the calcium/calmodulin-dependent myosin light chain kinase (MLCK) and regulation of non-m

140 in (RLC) phosphorylation, which is driven by myosin light chain kinase (MLCK) and Rho-associated kina

141 Here we have identified myosin light chain kinase (MLCK) as a regulator of membr

142 of transgenic mice that express a FRET-based myosin light chain kinase (MLCK) biosensor molecule, we

143 Inhibition of myosin light chain kinase (MLCK) blocked the effects of

144 on of an embryonic Ca2+/calmodulin-dependent myosin light chain kinase (MLCK) by blocking the ATP-bin

145 We hypothesized that myosin light chain kinase (MLCK) could be phosphorylated

146 ion phenotype was primarily due to increased myosin light chain kinase (MLCK) expression.

147 s contain two protein kinase domains, of the myosin light chain kinase (MLCK) family.

148 Ca(2+)/calmodulin-dependent skeletal muscle myosin light chain kinase (MLCK) gene expression.

149 The myosin light chain kinase (MLCK) gene, a muscle member o

150 the actin-binding proteins cortactin and EC myosin light chain kinase (MLCK) in mediating this respo

151 transgenic mice expressing calmodulin sensor myosin light chain kinase (MLCK) in smooth muscles, the

152 The role of myosin light chain kinase (MLCK) in the activation of th

153 mplex (ARPC) subunit 2, 3, and 5, as well as myosin light chain kinase (MLCK) in these cells.

154 ocusing on regulatory roles of IFN-gamma and myosin light chain kinase (MLCK) in TW myosin phosphoryl

155 Myosin light chain kinase (MLCK) inhibition blocked MLC

156 d in the absence or presence of the specific myosin light chain kinase (MLCK) inhibitor ML-7 under bo

157 chronized blebbing cells indicated that only myosin light chain kinase (MLCK) inhibitors decreased bl

158 ABSTRACT: Ca(2+) /calmodulin activation of myosin light chain kinase (MLCK) initiates myosin regula

159 on of myosin regulatory light chain (RLC) by myosin light chain kinase (MLCK) initiates smooth muscle

160 chains (RLC) by Ca(2+)/calmodulin-dependent myosin light chain kinase (MLCK) is a critical step in t

161 Myosin light chain kinase (MLCK) is expressed as long an

162 stimulated with a proapoptotic agent or when myosin light chain kinase (MLCK) is inhibited pharmacolo

163 at epithelial barrier dysfunction induced by myosin light chain kinase (MLCK) is required for the dev

164 ensor allowing simultaneous determination of myosin light chain kinase (MLCK) localization and its [C

165 Genetic knockout of long myosin light chain kinase (MLCK) or treatment of wild-ty

166 Ca(2+)/calmodulin-dependent myosin light chain kinase (MLCK) phosphorylates smooth m

167 Herein, we show that myosin light chain kinase (MLCK) plays a central role in

168 Activation of myosin II by myosin light chain kinase (MLCK) produces the force for

169 , where it bound to its binding motif on the myosin light chain kinase (MLCK) promoter region, leadin

170 9 of the myosin II regulatory light chain by myosin light chain kinase (MLCK) regulates actomyosin co

171 as a module for directing sequestered CaM to myosin light chain kinase (MLCK) through Ca(2+)-dependen

172 pproach used functional genomics analysis of myosin light chain kinase (MLCK) to identify short autoi

173 ulin-dependent protein kinase II (CaMKII) to myosin light chain kinase (MLCK) to myosin light chain,

174 Ca(2+)/calmodulin-dependent endothelial cell myosin light chain kinase (MLCK) triggers actomyosin con

175 ed enhanced activation of the ERK2 substrate myosin light chain kinase (MLCK) upon adhering to fibrin

176 Myosin light chain kinase (MLCK) was also required for u

177 myosin II, Rho-associated kinase (ROCK), and myosin light chain kinase (MLCK) were also recruited to

178 uscle myosin regulatory light chain (RLC) by myosin light chain kinase (MLCK) were determined.

179 ted by arp2/3 and contractility regulated by myosin light chain kinase (MLCK) were responsible for th

180 The mylk1 gene encodes a 220-kDa nonmuscle myosin light chain kinase (MLCK), a 130-kDa smooth muscl

181 iated response that leads to upregulation of myosin light chain kinase (MLCK), a hallmark of the path

182 reduction in the expression and activity of myosin light chain kinase (MLCK), a primary regulator of

183 , we found that inhibition of myosin ATPase, myosin light chain kinase (MLCK), and the knockout of my

184 between calmodulin (CaM) and skeletal muscle myosin light chain kinase (MLCK), as well as the conform

185 eptide of 26 amino acids derived from muscle myosin light chain kinase (MLCK), binds to calmodulin wi

186 lity pathway involving Rho kinase (ROCK) and myosin light chain kinase (MLCK), culminating in the act

187 aM for its ability to activate smooth muscle myosin light chain kinase (MLCK), one of the best unders

188 Last, myosin light chain kinase (MLCK), which can be directly

189 increased activity of intestinal epithelial myosin light chain kinase (MLCK), which is the primary m

190 CaM to transiently bind approximately 60% of myosin light chain kinase (MLCK), while a 1.8 ms hw ACT

191 Also, integrin engagement and v-Src induced myosin light chain kinase (MLCK)-dependent phosphorylati

192 Myosin light chain kinase (MLCK)-dependent phosphorylati

193 erijunctional actomyosin ring contributes to myosin light chain kinase (MLCK)-dependent tight junctio

194 nse to neutrophil activation with a focus on myosin light chain kinase (MLCK)-mediated myosin light c

195 of actin and myosin II that are regulated by myosin light chain kinase (MLCK)-mediated phosphorylatio

196 We showed previously that a myosin light chain kinase (MLCK)-myosin II pathway was r

197 ated by Rho-associated kinase (ROCK) but not myosin light chain kinase (MLCK).

198 on matrix rigidity, fibronectin binding and myosin light chain kinase (MLCK).

199 associated with increased phosphorylation of myosin light chain kinase (MLCK).

200 active truncation mutant of skeletal muscle myosin light chain kinase (MLCK).

201 y, block the action of calcium-calmodulin or myosin light chain kinase (MLCK).

202 tion of S19 on the regulatory light chain by myosin light chain kinase (MLCK).

203 duct derived from a gene within the gene for myosin light chain kinase (MLCK).

204 active truncation mutant of skeletal muscle myosin light chain kinase (MLCK).

205 ad spectrum of downstream targets, including myosin light chain kinase (MLCK).

206 ght junction (TJ) permeability by activating myosin light chain kinase (MLCK; official name MYLK3) ge

207 e Dbl family of GEFs and the titin family of myosin light chain kinases (MLCK).

208 Myosin light-chain kinase (MLCK) is a downstream target

209 osin II (MLC20) by Ca2+/calmodulin-dependent myosin light-chain kinase (MLCK) is essential for initia

210 phorylation of smooth muscle myosin (SMM) by myosin light-chain kinase (MLCK) proposes that MLCK is b

211 egulated the downstream nuclear factor-B and myosin light-chain kinase (MLCK) signalling, and these c

212 rom the amino acid sequence of smooth-muscle myosin light-chain kinase (MLCK) were characterized as i

213 e, in turn, ERK phosphorylates and activates myosin light-chain kinase (MLCK).

214 Here, we show that deletion of myosin light-chain kinases (MLCK) in the smooth muscle c

215 The 210,000 molecular weight myosin light chain kinase (MLCK210, also called EC MLCK

216 Short and long myosin light chain kinases (MLCKs) are Ca(2+)/calmodulin

217 Here we identify a myosin light-chain kinase MRCK-1 as a key regulator of C

218 The authors investigated the role of myosin light chain kinase (MYLK) and transforming growth

219 Single nucleotide polymorphisms in the myosin light chain kinase (MYLK) gene have been implicat

220 sequencing, we found homozygous variants in myosin light chain kinase (MYLK) in both families.

221 d by TRPC6, in turn, activates the nonmuscle myosin light chain kinase (MYLK), which not only increas

222 Nonmuscle myosin light-chain kinase (MYLK) mediates increased lung

223 nase that controls SMC contractile function (myosin light chain kinase [MYLK]) cause FTAAD, we sequen

224 pression of vinculin, focal adhesion kinase, myosin light chain kinase, myosin heavy chain or myosin

225 in), regulators of the contractile response (myosin light chain kinase, myosin phosphatase target sub

226 he recent identification of cardiac-specific myosin light chain kinase necessary for basal RLC phosph

227 eat consensus sequences in the N terminus of myosin light chain kinase necessary for high-affinity bi

228 Nonmuscle myosin light chain kinase (nmMLCK), a multi-functional c

229 Nonmuscle myosin light-chain kinase (nmMLCK), the predominant MLCK

230 mbers, we demonstrated the role of nonmuscle myosin light-chain kinase (nmMYLK) in Tat(1)(-)(7)(2) (1

231 Neither cellular myosin phosphatase, myosin light chain kinase, nor RhoA activities were chan

232 ression of contraction through inhibition of myosin light chain kinase normalized the effects of subs

233 his gene, which has been designated Obscurin-myosin light chain kinase (Obscurin-MLCK), would be pred

234 een (Ca(2+))4-calmodulin and skeletal muscle myosin light chain kinase or a peptide containing its co

235 Full-length myosin light chain kinase or a truncation mutant lacking

236 st, exposure to ML-9 or KN-62, inhibitors of myosin light chain kinase or Ca2+-calmodulin-dependent p

237 either the catalytic core of skeletal muscle myosin light chain kinase or Ca2+/calmodulin-dependent p

238 proteins similar to recombinant full-length myosin light chain kinase or enzyme purified from smooth

239 ented cytoskeletal defects, while inhibiting myosin light chain kinase or phosphorylation of focal ad

240 nied by an increase in protein expression of myosin light chain kinase (P<0.05) and casein kinase II-

241 The results clearly show that the myosin light chain kinase pathway and the Rho pathway di

242 to Arg-812 and Leu-813 in the smooth muscle myosin light chain kinase peptide.

243 hidden and unphosphorylated; on activation, myosin light chain kinase phosphorylates the monophospho

244 inal extension (Dmlc2(Delta2-46)), disrupted myosin light chain kinase phosphorylation sites (Dmlc2(S

245 ced stress fiber assembly, and inhibitors of myosin light chain kinase prevented this response but di

246 gion also shows 29, 25 and 29% identify with myosin light-chain kinase, protein kinase C, and cAMP-de

247 Inhibition of myosin light-chain kinase, protein kinases A, C, and G,

248 tebrate smooth muscle and nonmuscle forms of myosin light chain kinase, provides insight into the str

249 We tested the functionality of myosin light chain kinase pseudogene (MYLKP1) in human c

250 s, including phosphatidylinositol 3-kinases, myosin light-chain kinase, Ras-related C3 botulinum toxi

251 ent protein kinase II with its endogenous or myosin light chain kinase regulatory segments.

252 domain of CnA and the CaM-binding domain of myosin light chain kinase respectively.

253 rough RhoA GTPase, Rho-associated kinase, or myosin light chain kinase restored stiffness-dependent s

254 Phosphorylation of the RLC by myosin light chain kinase resulted in a smaller 1.5-fold

255 )/calmodulin (CaM)-dependent skeletal muscle myosin light chain kinase (skMLCK).

256 Smooth muscle myosin light chain kinase (SM-MLCK) is the key enzyme re

257 tive fragment of the monomeric smooth muscle myosin light chain kinase (smMLCK) (residues 472-972), w

258 investigated the regulation of smooth muscle myosin light chain kinase (smMLCK) by using spontaneousl

259 Smooth muscle myosin light chain kinase (smMLCK) is a calcium-calmodul

260 Smooth muscle myosin light chain kinase (smMLCK) is a member of a dive

261 ene that encodes nonmuscle and smooth muscle myosin light chain kinase (smMLCK) isoforms and regulate

262 22) repeats in the promoter of smooth muscle myosin light chain kinase (smMLCK), a key regulator of v

263 ficity for one of its targets, smooth muscle myosin light chain kinase (smMLCK).

264 ds one of its natural targets, smooth muscle myosin light chain kinase (smMLCK).

265 modulin binding site of rabbit smooth muscle myosin light chain kinase (smMLCKp) was studied using is

266 e calmodulin-binding domain of smooth muscle myosin light chain kinase (smMLCKp) with calcium-saturat

267 tractile proteins alpha-smooth muscle actin, myosin light chain kinase, smooth muscle myosin heavy ch

268 rotein kinase inhibitor staurosporine or the myosin light chain kinase-specific inhibitor KT5926 stop

269 A myosin light chain kinase-specific inhibitor, ML-9, dimi

270 ted to overexpress Ca2+/calmodulin-dependent myosin light chain kinase specifically in cardiomyocytes

271 Here, we demonstrate that myosin light chain kinase specifically mediates agonist-

272 Phosphorylation of myosin-bound RLC by myosin light chain kinase substantially inhibits binding

273 ends on cytoskeletal function; inhibition of myosin light chain kinase suppressed wave activity.

274 a peptide corresponding to the smooth muscle myosin light chain kinase target were carried out at 295

275 ytosis, and localized phosphorylation of the myosin light chain kinase, thereby impinging on the acto

276 el-bearing vesicles with the plasmalemma and myosin light chain kinase to regulate centripetal transp

277 n the sequence linking the catalytic core of myosin light chain kinase to the calmodulin-binding sequ

278 her assays: binding of fluorescently labeled myosin light chain kinases to actin-containing stress fi

279 m1a), expressed specifically in the MHB, and myosin light chain kinase together mediate MHBC cell len

280 runcated myosin light chain kinases, but not myosin light chain kinases truncated at the N terminus o

281 Inhibition of myosin II or myosin light chain kinase under elevated stimulation fre

282 P-dependent protein kinase and smooth muscle myosin light chain kinase undergo interactions with the

283 tes by the catalytic core of skeletal muscle myosin light chain kinase was altered with the regulator

284 he kinase, the polypeptide backbone chain of myosin light chain kinase was cleaved by genetic means t

285 member of this family, a protein related to Myosin light chain kinase, was also identified.

286 titutively active mutants of RhoA GTPase and myosin light chain kinase, we show that varying the expr

287 tyrosine kinases, protein kinase C, and the myosin light chain kinase were ineffective in blocking t

288 initiation required proliferation, Rac, and myosin light-chain kinase, whereas repolarization to a b

289 yosin II activity is regulated by the enzyme myosin light chain kinase, which activates myosin II by

290 enic process and that targeted inhibition of myosin light chain kinase, which affects this cytoskelet

291 xperiment, a calmodulin-binding peptide from myosin light chain kinase, which has no direct interacti

292 Colonic inflammation suppresses nuclear myosin light chain kinase, which increases the unphospho

293 sidues 2-8 (DeltaNCaM) binds skeletal muscle myosin light chain kinase with high affinity but fails t

294 However, direct inhibition of myosin light chain kinase with KT5926 resulted in a 90%

295 ntraction with isoproterenol, or by blocking myosin light chain kinase with ML-7.

296 MT movement was suppressed by inhibition of myosin light chain kinase with ML7 or by a peptide inhib

297 Assays of smooth muscle myosin light chain kinase with the calmodulin mutants M5

298 nhibition of actin polymerization as well as myosin light chain kinase with the drug ML7 limited both

299 transport during CR formation, we inhibited myosin light-chain kinase with ML7 and myosin II ATPase

300 hemical species that can bind actin, such as myosin light-chain kinase, with the contractile model le